Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer

Join Thomas W. Flaig, MD and Shandra Wilson, MD from University of Colorado Cancer Center as they present their expertise on a range of cases pertaining to bladder cancer.

Bladder cancer is the most common urological cancer. An estimated 76,960 new cases of urinary bladder cancer were diagnosed in the United States in 2016, with approximately 16,390 deaths occurring during this same period. The spectrum of bladder cancer includes non-muscle-invasive, muscle-invasive, and metastatic disease, and treatment of urothelial bladder cancer is influenced by the stage and grade of the cancer. Multimodality approaches and immunotherapies are demonstrating improved outcomes for patients with urothelial carcinomas. However, in order to effectively integrate these therapies into practice, clinician awareness of the importance of patient selection and subsequent monitoring for adverse events is essential.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review the treatment options for patients with bladder cancer and how they relate to tumor stage and grade.
  • Describe potential similarities and differences among emerging immunotherapies for urothelial carcinoma.
  • Discuss the types of adverse events associated with traditional oncology treatment modalities and immunotherapy in patients with urothelial carcinoma.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Celgene Corporation
  • Gilead Sciences, Medical Affairs
  • Lilly
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.72 ANCC contact hours
  • 0.75 Participation
Course opens: 
09/08/2017
Course expires: 
09/08/2018
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards (June 2017 - May 2018)

Thomas W. Flaig, MD
University of Colorado Cancer Center

Shandra Wilson, MD
University of Colorado Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses no relevant financial relationships:
Shandra Wilson, MD

The faculty listed below discloses the following relevant financial relationships:
Thomas W. Flaig, MD
Agensys: Grant/Research Support
Aragon Pharmaceuticals Inc.: Grant/Research Support
Astellas US LLC: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Aurora Oncology: Ownership/Partnership/Principal
BN ImmunoTherapeutics, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Dendreon Corporation: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
GTx, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Janssen/Cougar: Grant/Research Support
Medivation, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support
Roche/Genentech: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
Seattle Genetics: Grant/Research Support
SOTIO, LLC: Grant/Research Support
Tokai Pharmaceuticals, Inc.: Grant/Research Support

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kim Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Lisa Gurski, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hours of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.72 contact hours.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: 0836-0000-17-089-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.72 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing